Strong start to the year for Bayer

Group sales increase by 11.7 percent (Fx& portfolio adj.: 9.4 percent) to EUR 13,244 million / EBITDA before special items raised by 14.9 percent to EUR 3,893 million / Growth momentum across all segments / Very good business development at Pharmaceuticals / Significant increase in sales and earnings at Covestro / Net income 37.9 percent higher at EUR 2,083 million / Core earnings per share advance by 11.5 percent to EUR 2.62 / Group outlook for 2017 raised, driven by Covestro performance

Source: Bayer Company News - April 27, 2017 Category: Pharmaceuticals Source Type: news